Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma develops novel therapeutics and drug-delivery systems for stress-induced psychiatric disorders, chronic pain and central nervous system diseases, while also disclosing activity in cryptocurrency treasury and AI infrastructure initiatives. Company news frequently centers on SPC-15, an intranasal serotonin 5-HT4 receptor agonist program for PTSD and anxiety, as well as other pipeline work involving psychedelic-derived and traditional therapeutic approaches.
Recurring updates include patent allowances and applications in key jurisdictions, FDA and federal-policy context for psychedelic medicines, clinical-development planning, and new CNS discovery initiatives such as ibogaine-based approaches for traumatic brain injury. Corporate news also covers common-stock repurchase authorization, equity-financed asset purchases, the QwikAgents AI-agent platform, and cryptocurrency-related software assets.
Silo Pharma (NASDAQ: SILO) has successfully closed a $2 million public offering of 3,333,338 shares of common stock at $0.60 per share, along with Series A-1 and A-2 warrants. The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $0.60 per share. H.C. Wainwright & Co. served as the exclusive placement agent. The developmental stage biopharmaceutical company plans to use the net proceeds for general working capital purposes.
Silo Pharma (NASDAQ: SILO) has announced the pricing of a $2 million public offering consisting of 3,333,338 shares of common stock (or pre-funded warrants) along with Series A-1 and A-2 warrants. The offering is priced at $0.60 per share with associated warrants. Both Series A-1 and A-2 warrants have an exercise price of $0.60, with A-1 warrants expiring in 5 years and A-2 warrants in 18 months.
H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is expected to close around May 16, 2025. The company plans to use the net proceeds for general working capital purposes. The offering is made through an effective SEC registration statement on Form S-1.
Silo Pharma (NASDAQ: SILO) has selected Veloxity Labs to conduct bioanalytical work for its IND-enabling GLP toxicology and toxicokinetics study of SPC-15, the company's lead drug candidate. SPC-15 is being developed as an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
The company plans to initiate the FDA IND process for SPC-15 in 2025, and upon approval, will advance to a Phase 1 clinical trial. CEO Eric Weisblum expressed confidence in Veloxity Labs' ability to deliver fast turnaround times and precise data needed for the IND submission.
Silo Pharma (NASDAQ: SILO) has initiated a crucial 7-day safety and toxicology study for its lead drug candidate SPC-15, an intranasal PTSD treatment, at Frontage Laboratories. The study aims to gather additional data for the company's upcoming FDA investigational new drug (IND) application. Silo is simultaneously conducting a separate IND-enabling GLP-compliant toxicology study.
The company plans to submit its IND application in 2025, and upon approval, will proceed with a first-in-human Phase 1 clinical trial. SPC-15's development is backed by an exclusive global license from Columbia University for worldwide development, manufacturing, and commercialization rights.
Silo Pharma announced positive results from its preclinical study of SP-26, a novel extended-release ketamine implant for fibromyalgia treatment. The study, conducted in minipigs, met all endpoints including safety, tolerability, and sustained drug release.
Key findings include:
- No adverse events reported, with animals maintaining healthy weight and normal behavior
- Sustained ketamine release for up to 22 days post-implantation
- Minimal tissue inflammation at implant sites
- Peak drug levels achieved within 1 hour
SP-26 aims to provide sustained, sub-psychedelic ketamine levels in an abuse-deterrent format, potentially becoming the first at-home injectable ketamine-based therapeutic. The successful preclinical results position Silo to advance toward clinical studies for chronic pain and mental health treatments.
Silo Pharma (Nasdaq: SILO) has filed a patent application with the USPTO for SPC-14, an intranasal Alzheimer's disease treatment exclusively licensed from Columbia University. The patent, titled 'Compositions and Methods for the Treatment of Alzheimer's Disease and Other Neurogenerative Disease,' covers the drug's novel mechanism targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms.
The compound has demonstrated efficacy against luteinizing hormone in reducing learned helplessness, perseverative behavior, and hyponeophagia in early pre-clinical studies. SPC-14 was developed through a sponsored research agreement with Columbia University, followed by an exclusive global license agreement in 2024 for development, manufacturing, and commercialization rights.
Silo Pharma (Nasdaq: SILO) has announced a significant milestone in the development of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). The company has initiated first dosing in an IND-enabling GLP-compliant toxicology and toxicokinetics study.
Following a successful pre-IND meeting with the FDA in September 2024, Silo is pursuing the 505(b)(2) regulatory pathway for SPC-15's approval. This pathway is designed to potentially reduce clinical development timelines and costs. The current studies, if successful, will provide the final preclinical data required for submitting an IND application and advancing to first-in-human clinical trials.
Silo Pharma (Nasdaq: SILO) has secured a new U.S. patent (projected number 12,239,614) for its lead asset SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent, titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females,' will be issued on March 4, 2025.
This patent builds upon previously issued U.S. Patent 11,491,120 from November 2022, adding new claims and strengthening the company's intellectual property portfolio. The development supports Silo's collaborative research with Columbia University and advances their efforts toward clinical trials for SPC-15.
Silo Pharma (NASDAQ: SILO) has filed a new provisional patent application with the USPTO for its lead asset SPC-15, expanding its intellectual property portfolio. The patent covers a dual-action method and composition for treating stress-induced psychiatric disorders.
A preclinical study demonstrated that the combination of SPC-15, a serotonin type IV receptor (5-HT4R) agonist, with an N-methyl-D-aspartate receptor (NMDAR) antagonist showed significant improvements in behavioral outcomes and reduced severe stress-induced conditions. This technology was originally licensed through a collaboration with Columbia University.
The company has also recently filed a separate expanded provisional patent application focusing on chronic, combinatorial targeting of NMDARs and 5-HT4Rs to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
Silo Pharma (NASDAQ: SILO) reported positive initial results from its ongoing study of SP-26, a novel ketamine extended-release rod implant designed for chronic pain and fibromyalgia treatment. The non-GLP small animal testing, which began in December 2024, showed no serious side effects or discomfort following implantation in early January 2025.
The SP-26 implant is being developed as a self-administered, non-opioid therapeutic. The study is currently in the final stages of Absorption, Distribution, Metabolism, and Excretion (ADME) testing, with final safety and pharmacokinetic reports expected in March 2025.